Veradigm Inc (MDRX)

$4.80 +0.05 (1.05%)
Market Cap 517.28M
Revenue (ttm) 588.02M
Net Income (ttm) -86.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.70%
Debt to Equity Ratio 0.20
Volume 531,900
Avg Vol 126,112
Day's Range N/A - N/A
Shares Out 108.90M
Stochastic %K 45%
Beta 0.52
Analysts Sell
Price Target $5.83

Company Profile

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS,...

Industry: Health Information Services
Sector: Healthcare
Phone: 800 334 8534
Address:
222 Merchandise Mart Plaza, Suite 2024, Chicago, United States
sirspanky
sirspanky Nov. 17 at 2:22 PM
$HCTI at $2.09 — flirting with lows, but signals flash oversold and a daily golden cross just locked in. 👀 Spec bull case (DYOR): • Multiple gap: Still pricing <1× EV/S on ~$12–14M rev while Health-IT micros often trade ~2–3.5×. Even a plain re-rate = room above $2S. • Catalyst lane: Shareholder actions/S-3 cleanup could ease the $3 overhang; any progress on HIS/SaaS integration + ARR mix (CloudEz/DataEz/Readabl.ai) can nudge the multiple. • Downside asymmetry: Near ATL with improving technicals = defined risk, outsized upside if fundamentals/flows line up. Context tickers (not comps, just the theme): $MDRX (provider IT), $PLTR (AI ops in regulated spaces), $SNOW (health data cloud rails). Not advice—just the setup. 🧩📈
1 · Reply
sirspanky
sirspanky Nov. 14 at 7:40 PM
$BTC.X just lost the $100K psyc level and sits near 95k. Cool chart… but I’m parking attention in real operating progress: $HCTI. Why? • Undervalued: By my math, HCTI trades sub-1× EV/Sales on ~$12–14M rev, while health-IT micros often fetch ~2–3.5×. That’s a big gap for a cloud → data → AI stack (CloudEz / DataEz / Readabl.ai). • Resilient end-market: Hospitals must cut costs + boost throughput in tough tapes—exactly what HCTI sells. • Upcoming cleanups: Shareholder/filing steps + potential $3 warrant cash can extend runway and simplify the cap table—fuel for an execution-led re-rate. If you want “progress over pixels,” compare multiples and pipelines. Tags: $HCTI $BTC.X $MDRX $GEHC (Not advice—do your own DD.)
0 · Reply
sirspanky
sirspanky Nov. 13 at 8:20 PM
$HCTI holding the line at ~$2.19 on a market bloodbath day like an ER triage nurse: calm, caffeinated, and still checking vitals. 🩺😂 Why I’m smirking: • Valuation: Sub-1× EV/S on ~$12–14M rev while health-IT peers often fetch ~2–3.5×. You’re basically paying “contractor” prices for a cloud→data→AI stack (CloudEz / DataEz / Readabl.ai). • Setups: Stockholder call + filing cleanup could tidy the cap table; warrant path = potential runway boost right when hospitals are hunting efficiency. Context tags (not comps, just the theme): $MDRX, $GEHC, $VEEV Bad tape, good patients: hospitals still need margin ops and data plumbing. If you like efficiency plays, this one’s still in the waiting room—pager on. Not advice. 🚑📈
0 · Reply
sirspanky
sirspanky Nov. 13 at 6:41 PM
$HCTI @ ~$2.23 — Undervalued on a red tape + earnings day Why I still like the setup: • Multiple gap: On ~$12–14M rev, HCTI screens sub-1× EV/Sales (≈0.7–0.8× by my math) while Health-IT peers often fetch ~2–3.5×. You’re paying “services” multiples for a cloud → data → AI stack (CloudEz / DataEz / Readabl.ai). • Downturn tailwind: In tougher economies, hospitals must optimize—automation, coding accuracy, data interoperability, and cost analytics get prioritized to protect margins. That’s exactly HCTI’s lane. • Path to re-rate: Clean up the cap table (S-3/warrants), show ARR & margin traction, integrate the HIS/SaaS asset → a move toward even 2.0–2.75× EV/S implies materially higher equity value vs today. For context: premium vertical SaaS like $VEEV, digitized care ops like $GEHC, and provider IT names like $MDRX highlight what the market pays for efficiency. HCTI’s the sleeper version. (Not advice. DYOR.)
1 · Reply
sirspanky
sirspanky Nov. 7 at 4:58 PM
$HCTI TI Shareholder Call — What I’m Listening For 👇 Revenue & margin mix. Are we still tracking ~$12–14M rev and improving gross margin as cloud→data→AI (CloudEz / DataEz / Readabl.AI) grows vs legacy services? Pipeline/logos. New hospital wins, renewals, or partner co-sells (AWS/Azure) that expand the 100+ site footprint. LOI/HIS SaaS update. Timing, go-to-market, and how the front-end CX/agent layer plugs into the platform. Cap table cleanup. Status of S-3, stockholder approvals, and the path for $3.X warrants (potential ~$4.X.3M cash runway boost). Profitability path. OpEx discipline, cash burn, and any KPI targets (ARR, backlog, net retention). Why it matters: HCTI still screens sub-1× EV/Sales vs Health-IT peers at ~2–3.5×. Execution + clarity can force a re-rate. Context tickers: $MDRX $GEHC $VEEV (bigger names riding the same hospital digitization wave). Not advice.
1 · Reply
LordWellesley
LordWellesley Nov. 4 at 9:19 AM
It looks like Oracle Cerner $ORCL is taking over Veradigm $MDRX from the inside with the new CEO. chief innovation officer and now the HR lead coming out of that direction.
0 · Reply
sirspanky
sirspanky Oct. 30 at 5:14 PM
$HCTI pullback to ~$2.X.74 after tapping $3.X = microcap mechanics more than thesis change. $3.X round-number/profit-taking + sell algos. S-3/resale + $3.X warrant overhang = supply into strength. Thin book magnifies moves. Still like the setup: sub-1× EV/S on ~$12–14M vs health-IT micros ~2–3.5×. Catalysts ahead: stockholder vote/S-3 effectiveness (cleanup) + HIS/SaaS integration sharpening the cloud→data→AI story (CloudEz/DataEz/Readabl.AI). Watching $2.X.60–$2.X.70 as near support; re-test of $3.X if volume rotates back. Context: $MDRX $CPSI $GEHC. Not advice.
0 · Reply
sirspanky
sirspanky Oct. 29 at 6:05 PM
$HCTI popped to $3.06 and the setup still looks early. Why bullish: • Re-rate room: On ~$12–14M rev, HCTI was trading well sub-1× EV/S. Typical health-IT micros often fetch ~2–3.5×. A simple move to the low end of that band points to mid-$4S–$6S equity value (before any upside from integration/execution). • Catalysts: S-3/overhang mechanics are now better understood, shareholder approval path is clear, and the HIS/SaaS additions + CloudEz/DataEz/Readabl.AI sharpen the cloud→data→AI platform story. Peer context: If you track $MDRX and $CPSI on provider IT—or premium vertical SaaS like $VEEV—HCTI is the under-followed version earlier on the curve with headroom to normalize multiples. Not advice—just sharing the thesis & math. 🚀
0 · Reply
sirspanky
sirspanky Oct. 27 at 7:57 PM
$HCTI New coverage just hit on $HCTI — calling out a differentiated cloud→data→AI stack, re-accelerating revs, and a path to margin expansion (init PT ~$6). At ~$2.X.6–2.7, HCTI still screens sub-1× EV/S on ~$12–14M rev while health-IT micros often fetch ~2–3.5×. Catalysts ahead: S-3/overhang cleanup, stockholder vote, plus integration of the HIS/SaaS assets. If you watch vertical health IT like $MDRX and $CPSI—or premium vertical SaaS like $VEEV—this is the under-the-radar version earlier on the curve. Not advice; do your DD. 🚀 Source: Zacks Small Cap Research initiation (10/27/25). https://finance.yahoo.com/news/hcti-initiating-coverage-differentiated-information-092900656.html
0 · Reply
sirspanky
sirspanky Oct. 24 at 7:02 PM
$HCTI POWER HOUR 👀 $HCTI @ ~$2.X.69(sub-$2.X.70) – sleeper set-up • Undervalued: ~$12–14M rev vs sub-1× EV/Sales today, while provider/health-IT peers often fetch ~2–3.5× (and leaders like $VEEV command premium multiples). Priced like a contractor, building a cloud → data → AI platform (CloudEz / DataEz / Readabl.AI). • Catalysts + cash runway: Stockholder call/earnings + S-3 on file to clean up the ~$3 overhang. If new $3 warrants get exercised, that’s ~$4.3M of fresh fuel to scale the growing hospital/health-system business (100+ sites served) and the new HIS/SaaS push. Why talk now? Turbulent tape sends money to hospital-centric efficiency plays. If you like the theme in $MDRX, $GEHC, or premium SaaS like $VEEV, keep an eye on this under-the-radar version with leverage to upside. Tape’s thin into the close—small bids can matter. Do your own DD. 🚀
0 · Reply
Latest News on MDRX
No data available.
sirspanky
sirspanky Nov. 17 at 2:22 PM
$HCTI at $2.09 — flirting with lows, but signals flash oversold and a daily golden cross just locked in. 👀 Spec bull case (DYOR): • Multiple gap: Still pricing <1× EV/S on ~$12–14M rev while Health-IT micros often trade ~2–3.5×. Even a plain re-rate = room above $2S. • Catalyst lane: Shareholder actions/S-3 cleanup could ease the $3 overhang; any progress on HIS/SaaS integration + ARR mix (CloudEz/DataEz/Readabl.ai) can nudge the multiple. • Downside asymmetry: Near ATL with improving technicals = defined risk, outsized upside if fundamentals/flows line up. Context tickers (not comps, just the theme): $MDRX (provider IT), $PLTR (AI ops in regulated spaces), $SNOW (health data cloud rails). Not advice—just the setup. 🧩📈
1 · Reply
sirspanky
sirspanky Nov. 14 at 7:40 PM
$BTC.X just lost the $100K psyc level and sits near 95k. Cool chart… but I’m parking attention in real operating progress: $HCTI. Why? • Undervalued: By my math, HCTI trades sub-1× EV/Sales on ~$12–14M rev, while health-IT micros often fetch ~2–3.5×. That’s a big gap for a cloud → data → AI stack (CloudEz / DataEz / Readabl.ai). • Resilient end-market: Hospitals must cut costs + boost throughput in tough tapes—exactly what HCTI sells. • Upcoming cleanups: Shareholder/filing steps + potential $3 warrant cash can extend runway and simplify the cap table—fuel for an execution-led re-rate. If you want “progress over pixels,” compare multiples and pipelines. Tags: $HCTI $BTC.X $MDRX $GEHC (Not advice—do your own DD.)
0 · Reply
sirspanky
sirspanky Nov. 13 at 8:20 PM
$HCTI holding the line at ~$2.19 on a market bloodbath day like an ER triage nurse: calm, caffeinated, and still checking vitals. 🩺😂 Why I’m smirking: • Valuation: Sub-1× EV/S on ~$12–14M rev while health-IT peers often fetch ~2–3.5×. You’re basically paying “contractor” prices for a cloud→data→AI stack (CloudEz / DataEz / Readabl.ai). • Setups: Stockholder call + filing cleanup could tidy the cap table; warrant path = potential runway boost right when hospitals are hunting efficiency. Context tags (not comps, just the theme): $MDRX, $GEHC, $VEEV Bad tape, good patients: hospitals still need margin ops and data plumbing. If you like efficiency plays, this one’s still in the waiting room—pager on. Not advice. 🚑📈
0 · Reply
sirspanky
sirspanky Nov. 13 at 6:41 PM
$HCTI @ ~$2.23 — Undervalued on a red tape + earnings day Why I still like the setup: • Multiple gap: On ~$12–14M rev, HCTI screens sub-1× EV/Sales (≈0.7–0.8× by my math) while Health-IT peers often fetch ~2–3.5×. You’re paying “services” multiples for a cloud → data → AI stack (CloudEz / DataEz / Readabl.ai). • Downturn tailwind: In tougher economies, hospitals must optimize—automation, coding accuracy, data interoperability, and cost analytics get prioritized to protect margins. That’s exactly HCTI’s lane. • Path to re-rate: Clean up the cap table (S-3/warrants), show ARR & margin traction, integrate the HIS/SaaS asset → a move toward even 2.0–2.75× EV/S implies materially higher equity value vs today. For context: premium vertical SaaS like $VEEV, digitized care ops like $GEHC, and provider IT names like $MDRX highlight what the market pays for efficiency. HCTI’s the sleeper version. (Not advice. DYOR.)
1 · Reply
sirspanky
sirspanky Nov. 7 at 4:58 PM
$HCTI TI Shareholder Call — What I’m Listening For 👇 Revenue & margin mix. Are we still tracking ~$12–14M rev and improving gross margin as cloud→data→AI (CloudEz / DataEz / Readabl.AI) grows vs legacy services? Pipeline/logos. New hospital wins, renewals, or partner co-sells (AWS/Azure) that expand the 100+ site footprint. LOI/HIS SaaS update. Timing, go-to-market, and how the front-end CX/agent layer plugs into the platform. Cap table cleanup. Status of S-3, stockholder approvals, and the path for $3.X warrants (potential ~$4.X.3M cash runway boost). Profitability path. OpEx discipline, cash burn, and any KPI targets (ARR, backlog, net retention). Why it matters: HCTI still screens sub-1× EV/Sales vs Health-IT peers at ~2–3.5×. Execution + clarity can force a re-rate. Context tickers: $MDRX $GEHC $VEEV (bigger names riding the same hospital digitization wave). Not advice.
1 · Reply
LordWellesley
LordWellesley Nov. 4 at 9:19 AM
It looks like Oracle Cerner $ORCL is taking over Veradigm $MDRX from the inside with the new CEO. chief innovation officer and now the HR lead coming out of that direction.
0 · Reply
sirspanky
sirspanky Oct. 30 at 5:14 PM
$HCTI pullback to ~$2.X.74 after tapping $3.X = microcap mechanics more than thesis change. $3.X round-number/profit-taking + sell algos. S-3/resale + $3.X warrant overhang = supply into strength. Thin book magnifies moves. Still like the setup: sub-1× EV/S on ~$12–14M vs health-IT micros ~2–3.5×. Catalysts ahead: stockholder vote/S-3 effectiveness (cleanup) + HIS/SaaS integration sharpening the cloud→data→AI story (CloudEz/DataEz/Readabl.AI). Watching $2.X.60–$2.X.70 as near support; re-test of $3.X if volume rotates back. Context: $MDRX $CPSI $GEHC. Not advice.
0 · Reply
sirspanky
sirspanky Oct. 29 at 6:05 PM
$HCTI popped to $3.06 and the setup still looks early. Why bullish: • Re-rate room: On ~$12–14M rev, HCTI was trading well sub-1× EV/S. Typical health-IT micros often fetch ~2–3.5×. A simple move to the low end of that band points to mid-$4S–$6S equity value (before any upside from integration/execution). • Catalysts: S-3/overhang mechanics are now better understood, shareholder approval path is clear, and the HIS/SaaS additions + CloudEz/DataEz/Readabl.AI sharpen the cloud→data→AI platform story. Peer context: If you track $MDRX and $CPSI on provider IT—or premium vertical SaaS like $VEEV—HCTI is the under-followed version earlier on the curve with headroom to normalize multiples. Not advice—just sharing the thesis & math. 🚀
0 · Reply
sirspanky
sirspanky Oct. 27 at 7:57 PM
$HCTI New coverage just hit on $HCTI — calling out a differentiated cloud→data→AI stack, re-accelerating revs, and a path to margin expansion (init PT ~$6). At ~$2.X.6–2.7, HCTI still screens sub-1× EV/S on ~$12–14M rev while health-IT micros often fetch ~2–3.5×. Catalysts ahead: S-3/overhang cleanup, stockholder vote, plus integration of the HIS/SaaS assets. If you watch vertical health IT like $MDRX and $CPSI—or premium vertical SaaS like $VEEV—this is the under-the-radar version earlier on the curve. Not advice; do your DD. 🚀 Source: Zacks Small Cap Research initiation (10/27/25). https://finance.yahoo.com/news/hcti-initiating-coverage-differentiated-information-092900656.html
0 · Reply
sirspanky
sirspanky Oct. 24 at 7:02 PM
$HCTI POWER HOUR 👀 $HCTI @ ~$2.X.69(sub-$2.X.70) – sleeper set-up • Undervalued: ~$12–14M rev vs sub-1× EV/Sales today, while provider/health-IT peers often fetch ~2–3.5× (and leaders like $VEEV command premium multiples). Priced like a contractor, building a cloud → data → AI platform (CloudEz / DataEz / Readabl.AI). • Catalysts + cash runway: Stockholder call/earnings + S-3 on file to clean up the ~$3 overhang. If new $3 warrants get exercised, that’s ~$4.3M of fresh fuel to scale the growing hospital/health-system business (100+ sites served) and the new HIS/SaaS push. Why talk now? Turbulent tape sends money to hospital-centric efficiency plays. If you like the theme in $MDRX, $GEHC, or premium SaaS like $VEEV, keep an eye on this under-the-radar version with leverage to upside. Tape’s thin into the close—small bids can matter. Do your own DD. 🚀
0 · Reply
sirspanky
sirspanky Oct. 24 at 6:18 PM
$HCTI eading into the stockholders call & earnings with quiet-but-big setup vibes. Why we’re excited: Undervalued: On ~$12–14M rev, HCTI still screens sub-1× EV/Sales while Health-IT names often fetch ~2–3.5×. You’re paying “services” multiples for a cloud→data→AI platform (CloudEz / DataEz / Readabl.ai). Clean-up + cash option: Stockholder vote + S-3 effectiveness should clear the ~$3 overhang. If $3 warrants get exercised, that’s fresh cash to extend runway just as the HIS/SaaS LOI plugs in and expands front-end CX/agent workflows. What I’ll listen for: bookings mix, integration milestones, margin path, and any color on timing for the vote/S-3. Context tickers (not comps, just the lane): $VEEV (vertical SaaS premium), $MDRX (provider IT), $GEHC (digitized care). Sleeper micro-cap, efficient-care tailwind, and catalysts lining up. Not advice—watch the tape.
0 · Reply
LordWellesley
LordWellesley Sep. 30 at 8:22 PM
Looks like Veradigm $MDRX sold its stake in #Holmusk. (Cash inflow from portfolio activities). Any views?
0 · Reply
LordWellesley
LordWellesley Sep. 30 at 8:14 PM
$MDRX Any views on the press release?
0 · Reply
LordWellesley
LordWellesley Sep. 23 at 10:38 PM
$MDRX a business update on Sep 30th when Q3 is not yet tallied ?
1 · Reply
LordWellesley
LordWellesley Aug. 28 at 5:51 AM
What an unloved, hidden gem is Veradigm $MDRX. Of course, it is taking them forever to reset their finances and the resulting delisting to the OTC sinbin doesn’t help. However, despite soaring accounting/consulting costs related to the reset they are generating 100 mln plus in free cashflow. Under a new CEO they are quietly building a strong position at the cutting edge of (performance based) medical practice efficiency, RWD generation and RWE analysis for the pharma world. By springtime the admin worries will finally be over and some simple arithmetic (120 mln fcf x 15 divided by 110 mln shares) will triple the current price. $SPY
0 · Reply
Whiskey1679
Whiskey1679 Aug. 23 at 7:59 PM
Whiskey's Penny Stock Picks out Monday morning! High Volume Stocks this past week: $XTPT $MDRX $BMPA $SDRC $QSEP
0 · Reply
LordWellesley
LordWellesley Aug. 18 at 9:03 PM
Veradigm $MDRX appoints Don Trigg as its new ceo. A healthcare venture cap background and ex Cerner (Oracle) in short: the plot thickens… $ORCL https://investor.veradigm.com/news-releases/news-release-details/veradigm-appoints-don-trigg-chief-executive-officer Veradigm Appoints Don Trigg as Chief Executive Officer | Veradigm Inc.
0 · Reply
LordWellesley
LordWellesley Jul. 23 at 4:10 AM
Experts call for action to fulfil the potential of real-world data in pharma research $IQV $ICLR $MDRX https://becarispublishing.com/digital-content/blog-post/experts-call-action-fulfil-potential-real-world-data-research
0 · Reply
LordWellesley
LordWellesley Jul. 17 at 10:22 AM
$MDRX quietly building up a wide moat.
0 · Reply
LordWellesley
LordWellesley Jun. 19 at 2:11 PM
$MDRX Veradigm to Release Business Update June 23rd and Host Investor Call June 24th.
0 · Reply
DonCorleone77
DonCorleone77 May. 12 at 12:16 PM
$MDRX Veradigm advances GLP-1 real-world evidence generation with AI Veradigm announced an advancement in the use of artificial intelligence to scale the generation of real-world evidence for GLP-1 receptor agonists, including semaglutide and tirzepatide. By applying AI to electronic health record deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights-such as side effects, discontinuation reasons, and social determinants of health-that traditionally required intensive manual curation.
0 · Reply
LordWellesley
LordWellesley Apr. 22 at 11:28 PM
Veradigm $MDRX interim CEO Tom Langan is leaving the company with immediate effect. Does anyone know why? The press release only describes his severance package.
0 · Reply